Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
This article was originally published in The Pink Sheet Daily
Somewhat similar to Pfizer's recent agreement with Shanghai Pharmaceuticals Holdings, the deal will focus on manufacturing and broader commercialization of medicines.
You may also be interested in...
SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year
Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Perhaps the most interesting Q call of all was Pfizer Inc., which discussed in more detail whether it plans to spin out its emerging markets unit.
India-based Aurobindo Pharma Ltd. may find itself in a little hot water with business partner Pfizer Inc. after forcing a recall because bottles of an anti-depressant drug may have been mislabeled as a benign prostatic hyperplasia treatment